Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial

FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - MedRxiv, 2021 - medrxiv.org
Background Elevated proinflammatory cytokines have been associated with 2019
coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an …
被引用次数：13 相关文章
[HTML] europepmc.org

[HTML][HTML] Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo …

F Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - 2021 - europepmc.org
Background Elevated proinflammatory cytokines have been associated with 2019
coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an …

Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial

FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - 2021 - pesquisa.bvsalud.org
Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational,
randomised, adaptive, phase 3, double-blind, placebo-controlled trial | PREPRINT-MEDRXIV …
[PDF] archive.org

[PDF][PDF] Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled …

FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - scholar.archive.org
Background: Elevated proinflammatory cytokines have been associated with 2019
coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an …